SVB Securities analyst Faisal Khurshid initiated coverage of Fusion Pharmaceuticals with an Outperform rating and $6 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly